Neuroimaging Biomarker for Seizures (NIBMSZS)
Sponsor: Birmingham, Alabama VA Medical Center
This NA trial investigates Conversion Disorder and Epilepsy and is currently ongoing. Birmingham, Alabama VA Medical Center leads this study, which shows 12 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Unknown NA
-
Jul 2024 — Sep 2024 [monthly]
Unknown NA
Status: Unknown Status → Unknown
-
May 2024 — Jul 2024 [monthly]
Unknown Status NA
Status: Active Not Recruiting → Unknown Status
-
May 2022 — May 2024 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Oct 2021 — May 2022 [monthly]
Recruiting NA
▶ Show 7 earlier versions
-
Feb 2021 — Oct 2021 [monthly]
Recruiting NA
-
Jan 2021 — Feb 2021 [monthly]
Recruiting NA
-
Jul 2019 — Jan 2021 [monthly]
Recruiting NA
-
Feb 2019 — Jul 2019 [monthly]
Recruiting NA
-
Jun 2018 — Feb 2019 [monthly]
Recruiting NA
-
Apr 2018 — Jun 2018 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Sep 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Birmingham, Alabama VA Medical Center
- Brown University
- Ocean State Research Institute, Inc.
- Providence VA Medical Center
- Rhode Island Hospital
- United States Department of Defense
- University of Alabama at Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .